## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($266.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Can Elevance (ELV) Hike Prices to Accommodate Rising Costs?**
- Source: Insider Monkey | 20251230T070100 | Somewhat-Bullish | Relevance: 73%
- Artisan Value Fund recently invested in Elevance Health, Inc. (NYSE:ELV), highlighting its potential for recovery as pricing adjusts to increasing costs and its stock price multiple normalizes. This move comes as the fund swapped Cigna for Elevance due to differences in business mix, particularly regarding PBM reform risks. Elevance, one of the largest health insurers, is seen as undervalued with depressed earnings expected to recover.

**2. Marathon Asset Management Ltd Decreases Position in Healthcare Services Group, Inc. $HCSG**
- Source: MarketBeat | 20251229T111000 | Neutral | Relevance: 64%
- Marathon Asset Management Ltd has reduced its stake in Healthcare Services Group, Inc. (HCSG) by 26.3%, selling 335,589 shares, though it still owns 939,641 shares valued at approximately $15.8 million. Despite this, other institutional investors like Arrowstreet Capital significantly increased their positions, and institutions and hedge funds collectively own about 97.97% of the stock. Analysts hold a "Hold" consensus rating with a $19.40 target price, and the company recently beat EPS estimates while reporting an 8.5% year-over-year revenue growth.

**3. UnitedHealth (UNH) stock slips after hours as UnitedHealthcare delays remote monitoring policy**
- Source: ts2.tech | 20251229T180100 | Neutral | Relevance: 61%
- UnitedHealth Group Incorporated (UNH) shares fell after hours due to its UnitedHealthcare unit delaying a policy that would have tightened reimbursement for remote physiologic monitoring. This delay comes as investors anticipate UnitedHealth's full-year results and 2026 guidance, focusing on how the insurer plans to manage medical costs and regulatory risks. The market is also closely watching other industry developments, including scrutiny of insurer-owned pharmacy operations and a federal judge blocking Idaho's enforcement of unfair-competition law against UnitedHealthcare.

**4. Artisan Value Fund Sold Dollar General (DG) Due to Sustainability Concerns**
- Source: Yahoo Finance | 20251230T070500 | Neutral | Relevance: 61%
- Artisan Value Fund divested its position in Dollar General (NYSE: DG) due to concerns about the sustainability of its turnaround, citing tough competition and a weak lower-income consumer base. While acknowledging the company's progress, the fund believes other investment opportunities, particularly in AI stocks, offer greater upside potential and less downside risk. Despite the fund's exit, Dollar General saw a 24.98% one-month return and an 81.38% gain over 52 weeks, with 54 hedge funds holding positions at the end of the third quarter.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 8.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.56 indicates undervaluation relative to growth. Forward P/E 9.1x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.9B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.56 |
| Forward P/E | 9.1 |
| Current P/E | 9.3 |
| YoY Growth | 2.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.1% to 0.2% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.83), confirming momentum. RSI neutral at 54. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.16% (CS: 65) | Neutral |
| RSI_14 | 53.9 | Neutral |
| MACD Histogram | 0.83 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 0.920x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $276.54
- **Stop Loss:** $266.40 (3.7% risk)
- **Target:** $286.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $35,950.20
- **Portfolio %:** 35.95%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*